Replimune Group (NASDAQ:REPL) Price Target Raised to $21.00

Replimune Group (NASDAQ:REPL) had its price target upped by HC Wainwright from $17.00 to $21.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also issued reports on the company. BMO Capital Markets upped their target price on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Jefferies Financial Group lifted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $19.14.

Replimune Group Price Performance

Shares of REPL opened at $13.59 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The company has a 50 day moving average price of $12.28 and a 200-day moving average price of $11.33. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The stock has a market capitalization of $929.83 million, a PE ratio of -4.46 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. Equities analysts predict that Replimune Group will post -2.88 earnings per share for the current fiscal year.

Insider Activity

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of REPL. Charles Schwab Investment Management Inc. raised its holdings in shares of Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after acquiring an additional 52,498 shares during the last quarter. Geode Capital Management LLC raised its stake in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares during the last quarter. Barclays PLC lifted its holdings in Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares in the last quarter. LMR Partners LLP boosted its stake in Replimune Group by 145.8% during the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after purchasing an additional 48,920 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in shares of Replimune Group by 282.2% during the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after buying an additional 53,313 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.